"A new study will combine an Alzheimer’s medication that slows disease progression in some patients with two other drugs to see if their effects can be amplified. The trial will be the first to test drugs acting on two disease-driving proteins, amyloid and tau, for patients with late-onset Alzheimer’s, the most common type of dementia.
The trial will recruit 900 participants with early Alzheimer’s at UC San Francisco and other sites nationwide. It is funded by a $151 million grant from the National Institute on Aging, part of the National Institutes of Health.
In the trial, known as the Alzheimer’s Tau Platform (ATP), researchers will evaluate the effects of two anti-tau therapies and an anti-amyloid therapy like lecanemab (Leqembi), which was approved in January 2023 after demonstrating a 27% reduction in global impairment compared with placebo.
Lecanemab and related drugs clear amyloid and have also been shown to reduce tau. But drugs that specifically target tau may be more effective since their levels and locations correlate more closely with symptoms."